Progress and application of intelligent nanomedicine in urinary system tumors

IF 6.1 1区 医学 Q1 PHARMACOLOGY & PHARMACY Journal of Pharmaceutical Analysis Pub Date : 2024-03-12 DOI:10.1016/j.jpha.2024.100964
Yingming Xiao, Lei Zhong, Jinpeng Liu, Li Chen, Yi Wu, Ge Li
{"title":"Progress and application of intelligent nanomedicine in urinary system tumors","authors":"Yingming Xiao, Lei Zhong, Jinpeng Liu, Li Chen, Yi Wu, Ge Li","doi":"10.1016/j.jpha.2024.100964","DOIUrl":null,"url":null,"abstract":"Urinary system tumors include malignancies of the bladder, kidney, and prostate, and present considerable challenges in diagnosis and treatment. The conventional therapeutic approaches against urinary tumors are limited by the lack of targeted drug delivery and significant adverse effects, thereby necessitating novel solutions. Intelligent nanomedicine has emerged as a promising therapeutic alternative for cancer in recent years, and uses nanoscale materials to overcome the inherent biological barriers of tumors, and enhance diagnostic and therapeutic accuracy. In this review, we have explored the recent advances and applications of intelligent nanomedicine for the diagnosis, imaging, and treatment of urinary tumors. The principles of nanomedicine design pertaining to drug encapsulation, targeting and controlled release have been discussed, with emphasis on the strategies for overcoming renal clearance and tumor heterogeneity. Furthermore, the therapeutic applications of intelligent nanomedicine, its advantages over traditional chemotherapy, and the challenges currently facing clinical translation of nanomedicine, such as safety, regulation and scalability, have also been reviewed. Finally, we have assessed the potential of intelligent nanomedicine in the management of urinary system tumors, emphasizing emerging trends such as personalized nanomedicine and combination therapies. This comprehensive review underscores the substantial contributions of nanomedicine to the field of oncology and offers a promising outlook for more effective and precise treatment strategies for urinary system tumors.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"24 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Analysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpha.2024.100964","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Urinary system tumors include malignancies of the bladder, kidney, and prostate, and present considerable challenges in diagnosis and treatment. The conventional therapeutic approaches against urinary tumors are limited by the lack of targeted drug delivery and significant adverse effects, thereby necessitating novel solutions. Intelligent nanomedicine has emerged as a promising therapeutic alternative for cancer in recent years, and uses nanoscale materials to overcome the inherent biological barriers of tumors, and enhance diagnostic and therapeutic accuracy. In this review, we have explored the recent advances and applications of intelligent nanomedicine for the diagnosis, imaging, and treatment of urinary tumors. The principles of nanomedicine design pertaining to drug encapsulation, targeting and controlled release have been discussed, with emphasis on the strategies for overcoming renal clearance and tumor heterogeneity. Furthermore, the therapeutic applications of intelligent nanomedicine, its advantages over traditional chemotherapy, and the challenges currently facing clinical translation of nanomedicine, such as safety, regulation and scalability, have also been reviewed. Finally, we have assessed the potential of intelligent nanomedicine in the management of urinary system tumors, emphasizing emerging trends such as personalized nanomedicine and combination therapies. This comprehensive review underscores the substantial contributions of nanomedicine to the field of oncology and offers a promising outlook for more effective and precise treatment strategies for urinary system tumors.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
智能纳米医学在泌尿系统肿瘤中的进展与应用
泌尿系统肿瘤包括膀胱、肾脏和前列腺的恶性肿瘤,给诊断和治疗带来了巨大挑战。传统的泌尿系统肿瘤治疗方法受限于缺乏靶向给药和显著的不良反应,因此需要新的解决方案。近年来,智能纳米医学作为一种有前景的癌症治疗方法出现,它利用纳米级材料克服肿瘤固有的生物障碍,提高诊断和治疗的准确性。在这篇综述中,我们探讨了智能纳米医学在泌尿系统肿瘤诊断、成像和治疗方面的最新进展和应用。我们讨论了与药物封装、靶向和控释有关的纳米药物设计原理,重点是克服肾清除和肿瘤异质性的策略。此外,还综述了智能纳米药物的治疗应用、与传统化疗相比的优势,以及纳米药物临床转化目前面临的挑战,如安全性、监管和可扩展性。最后,我们评估了智能纳米医学在治疗泌尿系统肿瘤方面的潜力,强调了个性化纳米医学和联合疗法等新兴趋势。这篇全面的综述强调了纳米医学对肿瘤学领域的巨大贡献,并为泌尿系统肿瘤更有效、更精确的治疗策略提供了美好的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis Chemistry-Electrochemistry
CiteScore
16.20
自引率
2.30%
发文量
674
审稿时长
22 weeks
期刊介绍: The Journal of Pharmaceutical Analysis (JPA), established in 2011, serves as the official publication of Xi'an Jiaotong University. JPA is a monthly, peer-reviewed, open-access journal dedicated to disseminating noteworthy original research articles, review papers, short communications, news, research highlights, and editorials in the realm of Pharmacy Analysis. Encompassing a wide spectrum of topics, including Pharmaceutical Analysis, Analytical Techniques and Methods, Pharmacology, Metabolism, Drug Delivery, Cellular Imaging & Analysis, Natural Products, and Biosensing, JPA provides a comprehensive platform for scholarly discourse and innovation in the field.
期刊最新文献
Hepatic protein phosphatase 1 regulatory subunit 3G alleviates obesity and liver steatosis by regulating the gut microbiota and bile acid metabolism Retraction notice to “A DNA-based nanocarrier for efficient cancer therapy” [J. Pharm. Anal. 11 (2021) 330–339] Mapping conformational changes on bispecific antigen-binding biotherapeutic by covalent labeling and mass spectrometry Medcheck: a novel software for automatic de-formulation of traditional Chinese medicine (TCM) prescriptions by liquid chromatography-mass spectrometry 17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostate hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1